600% roi in 3 months, page-5

Boppy.

Good summary,,,im also in on the "averaging down" methodology :),, im not sure who said this first,, "but if there is no way out, the only way is further in"

The other biotechs without any late stage products have all been smashed, with extreme difficulty raising capital..i recall the previous Board of BOS asking shareholders for up to 15% by way of a rights issue and only getting ~3% ie less than $300k in during the last 2Q. Which is from my analysys of the last BOS annual report, less than 6 months of IP maintenance costs, let alone running the company or investing in development.

Surely, the best way forward for this IP is to put it in the hands of a party that can afford, if you beleive the GL Biochem numbers to invest in it of its own balance sheet ?